Print Page   |   Sign In   |   Create a Profile
News & Press: Industry News

RFS Pharma and Genoscience Enter Worldwide License Agreement

Monday, February 6, 2012   (0 Comments)
Posted by: Angela King
Share |


The agreement includes milestones, upfront license fees and royalties payable to both the companies.

The terms of the agreement are consistent with BioLineRx's standard in-license agreements.

BL-8030 is a potent and selective second generation NS3 protease inhibitor.

The NS3 protease is essential for the replication of the Hepatitis C virus (HCV) and is an important target for HCV therapies.

BL-8030 has been shown to have antiviral activity against various HCV genotypes.

RFS chemistry senior director Steven Coats said they worked closely with the group at Genoscience to determine the optimum characteristic that led to discovery of BL-8030 and related protease inhibitors.


more Calendar

Swings Fore STEM Golf Outing 2018

Boehringer-Ingelheim Industry Tour

Membership Software Powered by YourMembership  ::  Legal